Natural ligand of mouse CD1d1: Cellular glycosylphosphatidylinositol

Science

Volumn 279, Issue 5356, 1998, Pages 1541-1544

  Joyce, Sebastian ^a   Woods, Amina S ^b   Yewdell, Jonathan W ^c   Bennink, Jack R ^c   De Silva, A Dharshan ^a   Boesteanu, Alina ^a   Balk, Steven P ^d   Cotter, Robert J ^b   Brutkiewicz, Randy R ^c  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1 ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; LIGAND BINDING; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD1; BINDING SITES; GLYCOSYLPHOSPHATIDYLINOSITOLS; LIGANDS; MASS SPECTROMETRY; MICE; SOLUBILITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; T-LYMPHOCYTE SUBSETS;

ANIMALIA;

EID: 0032489652     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.279.5356.1541     Document Type: Article

References (35)

1. L. H. Martin, F. Calabi, C. Milstein, Proc. Natl. Acad Sci. U.S.A. 83, 9154(1986).
2. Z.-H. Zeng et al., Science 277, 339 (1997).
3. A. Bendelac et al., ibid. 268, 863 (1995).
4. M. Exley, G. Garcia, S. P. Balk, S. Porcelli, J. Exp. Med. 186, 109(1997).
5. M. Sykes, J. Immunol. 145, 3209 (1990).
6. T. Yoshimoto, A. Bendelac, C. Watson, J. Hu-Li, W. E. Paul, Science 270, 1845 (1995).
7. A. G. Baxter, S. J. Kinder, K. J. L. Hammond, R. Scollay, D. I. Godfrey, Diabetes 46, 572 (1997).
8. S. T. Smiley, M. H. Kaplan, M. J. Grusby, Science 275, 977(1997).
9. Y.-H. Chen, N. M. Chiu, M. Mandai, N. Wang, C.-R. Wang, Immunity 6, 459 (1997).
10. S. K. Mendiratta et al., ibid., p. 469.
11. H. Arase, N. Arase, K. Agasawara, R. A. Good, K. Onoe, Proc, Natl. Acad. Sci. U.S.A. 89, 6506 (1992).
12. E. G. Brooks et al., ibid. 90, 11787 (1993).
13. O. Lantz and A. Bendelac, J. Exp. Med. 180, 1097 (1994).
14. R. R. Brutkiewicz, J. R. Bennink, J. W. Yewdell, A. Bendelac, ibid. 182, 1913 (1995).
15. S. Joyce, P. Tabaczewski, R. H. Angeletti, S. G. Nathenson, I. Stroynowski, ibid. 179, 577 (1994).
16. 18 column (1,0 × 250 mm; Alltech) and eluted immediately by using a buffer B (0.05% TFA containing acetonitrile) gradient starting at 0% at 10 min to 37, 70, 90, and 100% at 73, 105, 115 and 120 min, respectively, at 50 μl/min.
17. S. Joyce et al., unpublished data.
18. 18 and cation-exchange column (1.0 × 250 mm; Alltech) by achieving 15, 60, and 100% buffer B at 15, 105, and 125 min, respectively, at 50 μl/min.
19. Mass spectra were acquired on a Kratos analytical MALDI-4 mass spectrometer equipped with a curved-field reflectron and a nitrogen laser. About 0.3 to 1.0 μl of each fraction (30 to 40 μl), either directly or after concentrating to∼15 μl, was applied onto the sample probe. Matrix, saturated α-cyano-4-hydroxycinnamic acid in 45% ethanol containing 8.8% formic acid (∼300 nl), was then applied to the sample. A replicate of the sample was similarly spotted, except that, to enhance ion signal, 300 nl of saturated ammonium sulfate was added before matrix (20). Spectra were acquired in positive and negative modes as well as in linear and reflectron modes after application of a 20-kV accelerating voltage. Because different fragments form stable positive and negative ions, when derived from the same molecule, positive and negative spectra provide complementary structural information. The mass analyses reported here are within a mass accuracy of 0.5 dalton.
20. A. S. Woods et al., Anal. Biochem. 226, 15 (1995).
21. N. Heller, R. J. Cotter, C. Fenselau, O. M. Uy, Anal. Chem. 59, 2806 (1987).
22. N. Heller, C. Murphy, R. J. Cotter, C. Fenselau, O. M. Uy, ibid. 60, 2787 (1988).
23. 18 RP-HPLC. Sample elution was initiated after the injection front returned to zero by increasing buffer B concentration to 37, 70, 90, and 100% at 63, 95, 105, and 110 min, respectively, at 50 μl/min.
24. A. W. Homans et al., Nature 333, 269 (1988).
25. 3H]Mannose-labeled, sCD1d1 and Db-sol-associated ligands were separated from the heavy and light chains by Microcon-10 (Amicon) filtration to specifically monitor GPI-associated radioactivity.
26. 3H]PI by Microcon-10 filtration, and radio-activity in the retained solution was measured.
27. 3H]fucose and rarely to other sugars (33), there are about seven times as many mannoses and fucoses in the heavy chain as in GPI (77). Thus ∼65% of CD1d1 is occupied by GPI before accounting for losses incurred during the purification steps. Assuming 65 to 70% recovery of the ligand [based on peptide recoveries from class I molecules (15, 34)], then >90% of CD1d1 is occupied by GPI.
28. A. R. Castaño et al., Science 269, 223 (1995).
29. S. Udenfriend and K. Kodukula, Anna. Rev. Bio-chem. 64, 563 (1995).
30. M. Sugita et al., Science 273, 349 (1996).
31. P. R. Wolfe and H. L. Ploegh, Annu. Rev. Cell Biol. 11, 267 (1995).
32. R. A. Henderson et al., Science 255, 1264 (1992).
33. A. Varki, Methods Enzymol. 230, 16 (1994).
34. T. S. Jardetzky, W. S. Lane, R. A. Robinson, D. R. Madden, D. C. Wiley, Nature 353, 326 (1991).
35. b, re-spectiveiy; and A. K. Menon for helpful discussions. Supported by grants from NIH (SJ., S.P.B., and R.J.C.), the Juvenile Diabetes Foundation International (S.J.), the American Cancer Society (S.J.), and the National Research Council-NIH (R.R.B.).